148 related articles for article (PubMed ID: 15134290)
1. Pegvisomant Pfizer/Sensus.
Goffin V; Touraine P
Curr Opin Investig Drugs; 2004 Apr; 5(4):463-8. PubMed ID: 15134290
[TBL] [Abstract][Full Text] [Related]
2. Pegvisomant. Pharmacia.
Goffin V; Touraine P
Curr Opin Investig Drugs; 2002 May; 3(5):752-7. PubMed ID: 12090548
[TBL] [Abstract][Full Text] [Related]
3. Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly.
Paisley AN; Trainer P; Drake W
Expert Opin Biol Ther; 2004 Mar; 4(3):421-5. PubMed ID: 15006735
[TBL] [Abstract][Full Text] [Related]
4. Pegvisomant in the treatment of acromegaly.
Parkinson C; Scarlett JA; Trainer PJ
Adv Drug Deliv Rev; 2003 Sep; 55(10):1303-14. PubMed ID: 14499709
[TBL] [Abstract][Full Text] [Related]
5. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.
Kopchick JJ; Parkinson C; Stevens EC; Trainer PJ
Endocr Rev; 2002 Oct; 23(5):623-46. PubMed ID: 12372843
[TBL] [Abstract][Full Text] [Related]
6. Clinical use of pegvisomant for the treatment of acromegaly.
Drake WM; Trainer PJ
Treat Endocrinol; 2003; 2(6):369-74. PubMed ID: 15981941
[TBL] [Abstract][Full Text] [Related]
7. The place of pegvisomant in the management of acromegaly.
Parkinson C; Trainer PJ
Expert Opin Investig Drugs; 2001 Sep; 10(9):1725-35. PubMed ID: 11772281
[TBL] [Abstract][Full Text] [Related]
8. USAN Council. List No.428. New names. Pegvisomant.
Clin Pharmacol Ther; 2000 Jul; 68(1):106. PubMed ID: 10991628
[No Abstract] [Full Text] [Related]
9. Growth hormone receptor antagonists.
van der Lely AJ; Kopchick JJ
Neuroendocrinology; 2006; 83(3-4):264-8. PubMed ID: 17047392
[TBL] [Abstract][Full Text] [Related]
10. Insights from growth hormone receptor blockade.
Muller AF; van der Lely AJ
Curr Opin Investig Drugs; 2004 Oct; 5(10):1072-9. PubMed ID: 15535428
[TBL] [Abstract][Full Text] [Related]
11. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
[TBL] [Abstract][Full Text] [Related]
12. Treatment of pituitary tumors: pegvisomant.
Paisley AN; Drake WM
Endocrine; 2005 Oct; 28(1):111-4. PubMed ID: 16311417
[TBL] [Abstract][Full Text] [Related]
13. Pegvisomant: a growth hormone receptor antagonist for the treatment of acromegaly.
Parkinson C; Trainer PJ
Growth Horm IGF Res; 2000 Apr; 10 Suppl B():S119-23. PubMed ID: 10984267
[TBL] [Abstract][Full Text] [Related]
14. Metabolic effects of GH antagonism in patients with acromegaly.
Trainer PJ
Growth Horm IGF Res; 2003 Aug; 13 Suppl A():S152-6. PubMed ID: 12914745
[TBL] [Abstract][Full Text] [Related]
15. Pegvisomant (Somavert) for acromegaly.
Med Lett Drugs Ther; 2003 Jul; 45(1160):55-6. PubMed ID: 12840714
[No Abstract] [Full Text] [Related]
16. [Growth hormone receptor antagonist in the treatment of acromegaly].
Hubina E; Tóth A; Kovács GL; Dénes J; Kovács L; Góth M
Orv Hetil; 2011 May; 152(18):709-14. PubMed ID: 21498159
[TBL] [Abstract][Full Text] [Related]
17. The role of growth hormone-receptor antagonism in relation to acromegaly.
Ayuk J; Sheppard MC
Expert Opin Pharmacother; 2004 Nov; 5(11):2279-85. PubMed ID: 15500374
[TBL] [Abstract][Full Text] [Related]
18. Place of pegvisomant in acromegaly.
Ho KK
Lancet; 2001 Nov; 358(9295):1743-4. PubMed ID: 11734225
[No Abstract] [Full Text] [Related]
19. The role of pegvisomant in the treatment of acromegaly.
Roelfsema F; Biermasz NR; Pereira AM; Romijn JA
Expert Opin Biol Ther; 2008 May; 8(5):691-704. PubMed ID: 18407771
[TBL] [Abstract][Full Text] [Related]
20. Pegvisomant: current and potential novel therapeutic applications.
Thankamony GN; Dunger DB; Acerini CL
Expert Opin Biol Ther; 2009 Dec; 9(12):1553-63. PubMed ID: 19916734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]